Online citations, reference lists, and bibliographies.
← Back to Search

Biowaiver Monographs For Immediate Release Solid Oral Dosage Forms: Isoniazid.

C. Becker, J. Dressman, G. Amidon, H. Junginger, S. Kopp, K. Midha, V. Shah, S. Stavchansky, D. Barends
Published 2007 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing isoniazid as the only active pharmaceutical ingredient (API) are reviewed. Isoniazid's solubility and permeability characteristics according to the Biopharmaceutics Classification System (BCS), as well as its therapeutic use and therapeutic index, its pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Isoniazid is "highly soluble" but data on its oral absorption and permeability are inconclusive, suggesting this API to be on the borderline of BCS Class I and III. For a number of excipients, an interaction with the permeability is extreme unlikely, but lactose and other deoxidizing saccharides can form condensation products with isoniazid, which may be less permeable than the free API. A biowaiver is recommended for IR solid oral drug products containing isoniazid as the sole API, provided that the test product meets the WHO requirements for "very rapidly dissolving" and contains only the excipients commonly used in isoniazid products, as listed in this article. Lactose and/or other deoxidizing saccharides containing formulations should be subjected to an in vivo BE study.
This paper references
Analytical profiles of drug substances and excipients
K. Florey (1992)
10.1002/JPS.2600590903
Interaction of isoniazid with magnesium oxide and lactose.
W. Wu (1970)
10.1021/MP034006H
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
N. A. Kasim (2004)
Absorption and excretion of drugs,10.
S. Naito (1964)
10.1002/cpt1976195part2610
Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis
G. A. Ellard (1976)
10.1002/JPS.20614
Biowaiver monographs for immediate release solid oral dosage forms: cimetidine.
E. Jantratid (2006)
10.7326/0003-4819-107-6-843
Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons.
W. Stead (1987)
10.1007/BF03307036
Antituberculosis drugs
J. Robson (1963)
10.1007/BF01059476
Plasma and salivary concentrations of isoniazid in man: Preliminary findings in two slow acetylator subjects
H. Boxenbaum (2005)
10.1002/JPS.20477
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol).
L. Kalantzi (2006)
Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.
T. Mariappan (2003)
10.1002/JPS.20615
Biowaiver monographs for immediate release solid oral dosage forms: amitriptyline hydrochloride.
R. Manzo (2006)
10.1002/j.1552-4604.1998.tb04385.x
When Are Bioavailability Studies Required? A German Proposal
C. Gleiter (1998)
10.1002/JPS.20392
Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride.
H. Kortejärvi (2005)
10.1016/J.IJPHARM.2004.02.019
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
S. Agrawal (2004)
10.5860/choice.44-5373
The Merck index : an encyclopedia of chemicals, drugs, and biologicals
S. Budavari (1983)
Martindale: The Complete Drug Reference
Sean C. Sweetman (1999)
10.1002/JPS.20444
Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen.
H. Potthast (2005)
Inactivation of isoniazid by condensation in a syrup preparation.
K. V. Rao (1971)
10.1002/JPS.2600661228
Bioavailability of three isoniazid formulations.
S. Sved (1977)
10.1007/s11095-004-9004-4
Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System
C. Wu (2004)
10.2165/00003088-198409060-00003
Clinical Pharmacokinetics of the Antituberculosis Drugs
M. Holdiness (1984)
10.1248/CPB.13.551
Absorption and Excretion of Drugs. XXII. Absorption of Isoniazid and its Derivatives
K. Kakemi (1965)
Bioequivalence of isoniazid in a two drug fixed dose combination and in a single drug dosage form.
S. Agrawal (2001)
10.1016/0962-8479(95)90551-0
Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.
C. Zent (1995)
10.1002/JPS.20131
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol.
H. Vogelpoel (2004)
10.1164/ARRD.1974.109.1.41
Effects of antacids on gastrointestinal absorption of isoniazid in rat and man.
A. Hurwitz (1974)
10.7326/0003-4819-89-3-430_2
Isoniazid and ethambutol absorption with jejunoileal bypass.
R. Polk (1978)
[Absorption of anti-tuberculous drugs after gastric surgery (author's transl)].
F. Kleber (1979)
10.1002/CPT1976195PART2610
Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.
Ellard Ga (1976)
10.1016/J.EJPB.2004.03.001
Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Marc Lindenberg (2004)
10.2165/00003088-197904060-00001
Clinical Pharmacokinetics of Isoniazid
W. Weber (1979)
10.1016/S0378-5173(01)00939-5
Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
S. Agrawal (2002)
[Absorption of anti-tuberculous drugs after gastric surgery (author's transl)].
Kleber Fx (1979)
Absorption and excretion of drugs. XXII. Absorption of isoniazid and its derivatives. (1).
K. Kakemi (1965)
10.1248/CPB.45.1332
Application of Tumbling Melt Granulation (TMG) Method for Controlled Enteric-Release Beads by Coating Mixture of Hydrogenated Castoer Oil and Higher Fatty Acid
T. Maejima (1997)
10.1201/9780824741969.AXH
Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System
Michael Levin (2001)
10.1007/BF01086149
Pharmacokinetics of isoniazid metabolism in man
G. A. Ellard (2005)
10.1002/cpt1969106841
A study of the availability of six commercial formulations of isoniazid
R. Gelber (1969)
10.7326/0003-4819-44-2-433_1
The International Pharmacopoeia.
W. A. R. Thomson (1952)
10.1164/ART.1952.65.4.429
The absorption, distribution, excretion, and short-term toxicity of isonicotinic acid hydrazide (nydrazid) in man.
D. Elmendorf (1952)
Bio-availability of INH in liquid dosage form.
S. R. Chavan (1974)
10.1002/JPS.20343
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride.
R. Verbeeck (2005)
10.1093/JAC/10.5.427
Influence of various diets on the bioavailability of isoniazid.
P. Männisto (1982)
10.5414/CPP40474
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
S. Agrawal (2002)



This paper is referenced by
10.20959/WJPPS20175-8964
FORMULATION AND IN-VITRO CHARACTERIZATION OF BIODEGRADABLE ISONIAZID NANOPARTICLES IN COW URINE
V. S. Babu (2017)
10.3390/bios7020021
An Enzyme-Induced Novel Biosensor for the Sensitive Electrochemical Determination of Isoniazid
Rajasekhar Chokkareddy (2017)
10.1002/9783527801756.CH8
Solubility, Permeability, and Their Interplay
A. Beig (2018)
10.1016/j.ejpb.2009.04.015
Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability.
P. Zakeri-Milani (2009)
Formulation And Evaluation Of Controlled Release Matrices Of Selected Propionic Acid Derivatives
Wahab Abdul (2012)
10.3390/pharmaceutics12040369
Multi-Methodological Quantitative Taste Assessment of Anti-Tuberculosis Drugs to Support the Development of Palatable Paediatric Dosage Forms
Alison V. Keating (2020)
10.1080/03639040701744095
Enhanced Dissolution of Ibuprofen Using Solid Dispersion with Polyethylene Glycol 20000
Madhuri Newa (2008)
Synthesis and Evaluation of the Properties of Chitosan-Cellulose Whisker Microparticles for Controlled Release of Isoniazid
T. Maji (2015)
10.1039/C2CE06391C
Fast dissolving eutectic compositions of two anti-tubercular drugs
S. Cherukuvada (2012)
10.1515/acph-2016-0008
Physicochemical characterization and dissolution studies of acyclovir solid dispersions with Pluronic F127 prepared by the kneading method
B. Karolewicz (2016)
UvA-DARE ( Digital Academic Repository ) Quantification of isoniazid , pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry
M. G. G. Sturkenboom (2015)
10.1002/jps.21624
Biowaiver monographs for immediate release solid oral dosage forms: rifampicin.
C. Becker (2009)
10.1007/S10847-010-9795-3
Host–guest complexes of the antituberculosis drugs pyrazinamide and isoniazid with cucurbit[7]uril
N. Wheate (2010)
FACULDADE DE CIÊNCIAS FARMACÊUTICAS Programa de Pós-Graduação em Fármaco e Medicamentos Área de Produção e Controle Farmacêuticos Sistema de Classificação Biofarmacêutica e Bioisenções
Denise Bonamici (2009)
Analytical Problem-Solving Procedures for Undergraduates by 1 H NMR
A. Živković (2020)
10.3109/10837450.2012.659254
Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations
Y. Wang (2013)
10.1039/C2RA20702H
Preparation and evaluation of the effect of particle size on the properties of chitosan-montmorillonite nanoparticles loaded with isoniazid
Nibedita Banik (2012)
10.1002/jps.21392
Biowaiver monographs for immediate release solid oral dosage forms: aciclovir.
J. Arnal (2008)
Formulation development and evaluation of Isoniazid delayed release pellets
A. Szent-Gyorgyi (2011)
10.1016/j.xphs.2017.04.068
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate.
D. Thambavita (2017)
10.1016/j.xphs.2017.05.037
Effect of Grinding on the Solid-State Stability and Particle Dissolution of Acyclovir Polymorphs.
Federico Magnoni (2017)
Stability of anti–tuberculosis actives in the PheroidTM delivery system
Gizela Bianca Sheen (2010)
10.1016/j.ejps.2014.02.004
Pharmacokinetic simulations to explore dissolution criteria of BCS I and III biowaivers with and without MDR-1 efflux transporter.
H. Kortejärvi (2014)
10.1016/j.ejpb.2015.04.034
Transformation of acidic poorly water soluble drugs into ionic liquids.
A. Balk (2015)
Oral Delivery of ascorbic acid stabilized rifampicin nanoparticles for enhanced bioavailability of rifampicin.
R. Subashini (2013)
10.1007/s10953-020-01015-w
Volumetric, UV–Vis and FT IR Studies of Isoniazid in Diethylsulfoxide Solutions
S. A. Markarian (2020)
K-Carrageenan and Chitosan
N. Devi (2016)
10.1016/j.ijpharm.2014.01.022
A non-binary biopharmaceutical classification of drugs: the ABΓ system.
P. Macheras (2014)
10.1002/jps.23769
The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs.
A. Sediq (2014)
Risk Outlining and Uncertainty Contour for Quantification of Acyclovir Using LC-MS: Solicitation to in Vitro Cell Line Studies
Karan Mittal (2015)
10.1002/bdd.1803
Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus
D. Mudie (2012)
10.1002/bdd.2170
Application of data mining approach to identify drug subclasses based on solubility and permeability
Biljana Gatarić (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar